Alpha -Tocopherol Acetate Dl- Ascorbic Acid Beta C

證據等級: L5

預測適應症: 0 個

Multi-Vitamin/Mineral Complex (DHA + Folate Formula): No TxGNN Predictions Generated

One-Sentence Summary

This candidate is a 17-component fixed-dose combination of vitamins, minerals, and DHA (doconexent), consistent with the profile of a prenatal nutritional supplement. The TxGNN pipeline could not generate repurposing predictions because no single DrugBank ID could be assigned to this combination product. With zero Taiwan market authorizations and no predicted indications, this candidate cannot proceed to repurposing evaluation at this stage.

Quick Overview

Item	Content
Original Indication	Not established (no Taiwan regulatory approval)
Predicted New Indication	None generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — No predictions or supporting studies available
Taiwan Market Status	Not marketed (未上市)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction is available for this candidate. The compound is a fixed-dose combination of 17 micronutrients, spanning fat-soluble vitamins (beta-carotene, cholecalciferol, DL-α-tocopherol acetate), water-soluble vitamins (ascorbic acid, thiamine mononitrate, riboflavin, niacinamide, pyridoxine HCl, folic acid, levomefolate calcium, cyanocobalamin), an omega-3 fatty acid (doconexent/DHA), and essential minerals (iron, magnesium oxide, cupric oxide, zinc oxide, potassium iodide). This profile is characteristic of a prenatal or women’s health nutritional supplement.

The TxGNN pipeline requires a single DrugBank ID as its entry point for knowledge graph traversal and deep learning prediction. Although the DrugBank query returned one result (result_count: 1), no DrugBank ID was successfully assigned (drugbank_id: null), suggesting the match was ambiguous or linked to the combination product as a formulation entity rather than a single-molecule node that TxGNN can process.

The absence of a generated prediction does not mean repurposing is implausible. Several individual components — including doconexent (DHA/omega-3 fatty acid), vitamin D3 (cholecalciferol), and folate — each have independent and substantial repurposing literature. However, evaluating them through a single-entity TxGNN run on the combination product is technically infeasible with the current pipeline design.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The pipeline could not process this 17-component combination formula as a unified repurposing candidate, as no DrugBank ID mapping was established and no TxGNN predictions were generated.

To proceed, the following is needed:

Decompose the formula into individual active ingredients and submit each as a separate TxGNN query (priority candidates: doconexent, cholecalciferol, folic acid/levomefolate calcium)
Confirm individual DrugBank IDs for each component (e.g., doconexent → DB00329, cholecalciferol → DB00169)
Determine whether this specific combination has regulatory approval in any jurisdiction to establish an original indication baseline
If a single-agent hypothesis is identified (e.g., DHA for neurodevelopmental or inflammatory indications), initiate a dedicated evidence pack for that component
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.